Skip to main content

Futura Medical expects FDA approval for topical ED treatment during Q2

--News Direct--

Futura Medical PLC (AIM:FUM, OTC:FAMDF) CEO James Barder speaks to Proactive's Thomas Warner after announcing the European online launch of topical erectile dysfunction (ED) treatment MED3000, under the brand name Eroxon.

Barder also gives an update on the company's discussions with the FDA regarding MED3000, saying that he expects approval to come during the second quarter.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/futura-medical-expects-fda-approval-for-topical-ed-treatment-during-q2-454503703

Recent Quotes

View More
Symbol Price Change (%)
AMZN  206.62
+1.76 (0.86%)
AAPL  259.82
-0.76 (-0.29%)
AMD  200.76
-2.61 (-1.28%)
BAC  52.33
-0.44 (-0.83%)
GOOG  310.19
+6.63 (2.19%)
META  650.86
+6.08 (0.94%)
MSFT  396.74
-1.72 (-0.43%)
NVDA  188.03
+0.12 (0.07%)
ORCL  152.36
-4.18 (-2.67%)
TSLA  409.22
-2.49 (-0.60%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.